Amphastar Pharmaceuticals Expects EPS of $0.69 in Upcoming Quarter

Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) expects EPS of $0.69 in the upcoming quarterly report. Last quarter, EPS missed expectations, resulting in a 9.72% stock decline. Currently, the stock trades at $25.12 and has fallen 41.47% over the last year. Analysts rate the stock as neutral, with a target price of $32.0, suggesting a potential upside of 27.39%. Investors await positive guidance to influence future stock performance. Unusual Whales

Impact Analysis

1. Business Overview Analysis

• Amphastar Pharmaceuticals focuses on developing, manufacturing, and marketing generic and proprietary injectable and inhalation products. Their revenue streams include hospital sales and retail pharmacy sales.Unusual Whales+ 2
• Market position is challenged by a significant stock price decline over the past year. Analysts offer a neutral rating but imply potential for upside with a target stock price increase.Unusual Whales
• Recent significant events include a previous quarter’s EPS miss and institutional interest, with firms like Barclays PLC increasing holdings, indicating some market confidence.Market Beat+ 2

2. Financial Statement Analysis

• Income Statement: Analysts expect EPS of $0.69, an increase from previous estimates. Last quarter’s EPS miss caused a stock decline, showing sensitivity to earnings performance.Market Beat
• Balance Sheet: The company’s market cap is about $11.3 billion and has a relatively low P/E ratio of 7.96, which could indicate undervaluation given historical performance.Market Beat
• Cash Flow: Institutional investments suggest a stable cash flow, as entities increase holdings, signaling confidence in financial management.Market Beat+ 2
• Financial Ratios:
• Profitability: ROE and ROA not explicitly mentioned; however, P/E suggests potential undervaluation.
• Liquidity: Current and Quick Ratios not provided; investors should assess liquidity constraints.
• Solvency: Debt/Equity and Interest Coverage ratios are not available but should be evaluated for operational resilience.
• Efficiency: No direct metrics available for Asset or Inventory Turnover.

3. Valuation Assessment

• Current valuation metrics compared against analyst expectations show potential for growth, with target price suggesting a 27.39% increase from current levels.Unusual Whales

4. Opportunity Analysis

• Market expansion and product opportunities are possible, given analyst ratings and institutional investment interest, which could drive future stock performance.Market Beat+ 2

Overall, Amphastar Pharmaceuticals presents both risks and opportunities, with stock sensitive to earnings performance and potential undervaluation encouraging investment consideration.